Related Experiment Video
Updated: May 3, 2026

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
36.6K
Uncovering Plaque-Glia Niches in Human Alzheimer's Disease Brains Using Spatial Transcriptomics
Biorxiv : the Preprint Server for Biology
|September 24, 2024
Summary
Alzheimer's Disease research reveals that amyloid-beta plaques trigger glial cell activation, leading to neuronal and synaptic loss. This study highlights the complex glial response around plaques, offering insights into neurodegeneration. Keywords: Alzheimer's Disease, amyloid-beta plaques, glial activation, neurodegeneration.
Area of Science:
- Neuroscience
- Pathology
- Genomics
Background:
- Alzheimer's Disease (AD) is characterized by amyloid-beta (Aβ) plaques and glial activation.
- The precise interaction between Aβ plaques and glial cells in the human brain remains unclear.
Purpose of the Study:
- To investigate the transcriptomic profiles of glial cells surrounding Aβ plaques in human AD brains.
- To elucidate the role of glial responses in Aβ-mediated neurodegeneration and synaptic loss.
Main Methods:
- Spatial transcriptomics (ST) and immunohistochemistry (IHC) were applied to postmortem human brain sections.
- Coupling ST with adjacent-section IHC allowed for detailed analysis of Aβ, glial cells (GFAP, IBA1), and neuronal markers.
Main Results:
- Low Aβ areas showed transcriptomic signs of greater neuronal loss, while high-glia areas indicated increased inflammation and neurodegeneration.
- Glial responses around plaques mirrored known mouse gene modules (PIG, OLIG, DAM, DAA) and human microglia states.
- Aβ exposure in iPSC-derived microglia-like cells mimicked the observed glial response in AD brains.
Conclusions:
- Microglia response to Aβ oligomers likely initiates glial activation in plaque-glia niches, exacerbating synaptic and neuronal loss.
- The study provides a foundation for understanding pathological heterogeneity and causal effects in neurodegenerative diseases.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35

